

# JÃ¼rgen H E Kuball

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4270024/publications.pdf>

Version: 2024-02-01

141  
papers

7,682  
citations

66343

42  
h-index

56724

83  
g-index

152  
all docs

152  
docs citations

152  
times ranked

9615  
citing authors

#	ARTICLE	IF	CITATIONS
1	Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human $\gamma\delta$ T-cell subset. <i>Blood</i> , 2012, 120, 2269-2279.	1.4	443
2	Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. <i>Nature Medicine</i> , 2012, 18, 807-815.	30.7	398
3	High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3889-3897.	1.6	392
4	Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. <i>Blood</i> , 2007, 110, 201-210.	1.4	383
5	Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. <i>Nature Immunology</i> , 2001, 2, 962-970.	14.5	348
6	Facilitating matched pairing and expression of TCR chains introduced into human T cells. <i>Blood</i> , 2007, 109, 2331-2338.	1.4	318
7	Translating gammadelta ( $\gamma\delta$ ) T cells and their receptors into cancer cell therapies. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 169-184.	46.4	265
8	Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. <i>Blood</i> , 2012, 119, 1599-1606.	1.4	254
9	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Haematologica</i> , 2020, 105, 297-316.	3.5	230
10	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. <i>Bone Marrow Transplantation</i> , 2019, 54, 1525-1552.	2.4	218
11	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	30.7	216
12	Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results of a Multicenter Phase II Study. <i>Journal of Clinical Oncology</i> , 2001, 19, 1750-1758.	1.6	201
13	Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. <i>Bone Marrow Transplantation</i> , 2020, 55, 126-136.	2.4	196
14	Redirecting $\gamma\delta$ T cells against cancer cells by transfer of a broadly tumor-reactive $\gamma\delta$ T-cell receptor. <i>Blood</i> , 2011, 118, 50-59.	1.4	184
15	Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haematopoietic cell transplantation: a retrospective, pharmacodynamic cohort analysis. <i>Lancet Haematology</i> , 2017, 4, e183-e191.	4.6	154
16	Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. <i>Lancet Haematology</i> , 2019, 6, e573-e584.	4.6	140
17	Cooperation of Human Tumor-Reactive CD4+ and CD8+ T Cells after Redirection of Their Specificity by a High-Affinity p53A2.1-Specific TCR. <i>Immunity</i> , 2005, 22, 117-129.	14.3	136
18	Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. <i>Journal of Experimental Medicine</i> , 2009, 206, 463-475.	8.5	132

#	ARTICLE	IF	CITATIONS
19	The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. <i>Bone Marrow Transplantation</i> , 2019, 54, 1575-1585.	2.4	129
20	Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	125
21	Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. <i>Blood</i> , 2019, 133, 1457-1464.	1.4	125
22	Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. <i>Bone Marrow Transplantation</i> , 2018, 53, 1139-1148.	2.4	117
23	Successful Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients With Bladder Cancer by Intravesical Vector Instillation. <i>Journal of Clinical Oncology</i> , 2002, 20, 957-965.	1.6	112
24	RhoB Mediates Phosphoantigen Recognition by VÎ³9VÎ²2Î±T Cell Receptor. <i>Cell Reports</i> , 2016, 15, 1973-1985.	6.4	112
25	Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. <i>Journal of Clinical Oncology</i> , 2019, 37, 367-374.	1.6	110
26	Haematopoietic stem cell transplantation for autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2017, 13, 244-256.	8.0	108
27	Molecular Design of the CÎ±Î² Interface Favors Specific Pairing of Introduced TCRÎ±Î² in Human T Cells. <i>Journal of Immunology</i> , 2008, 180, 391-401.	0.8	87
28	Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?. <i>Nature Reviews Rheumatology</i> , 2016, 12, 593-604.	8.0	81
29	Î³9 and Î²2CDR3 domains regulate functional avidity of T cells harboring Î³9Î²2TCRs. <i>Blood</i> , 2012, 120, 5153-5162.	1.4	74
30	Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 161-171.	4.2	67
31	Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD. <i>Blood</i> , 2016, 128, 1979-1986.	1.4	66
32	A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of VÎ³9VÎ²2-T cells. <i>Oncolimmunology</i> , 2018, 7, e1375641.	4.6	61
33	Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2365-2370.	2.0	61
34	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. <i>Bone Marrow Transplantation</i> , 2020, 55, 485-495.	2.4	61
35	Early Reconstitution of NK and Î³Î² T Cells and Its Implication for the Design of Post-Transplant Immunotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1152-1162.	2.0	56
36	Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model. <i>Oncolimmunology</i> , 2018, 7, e1434465.	4.6	54

#	ARTICLE	IF	CITATIONS
37	GMP-Grade Manufacturing of T Cells Engineered to Express a Defined Î³Î±TCR. <i>Frontiers in Immunology</i> , 2018, 9, 1062.	4.8	53
38	High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia â€” an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Oncotarget</i> , 2016, 7, 27255-27266.	1.8	53
39	Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. <i>Journal of Hematology and Oncology</i> , 2016, 9, 118.	17.0	50
40	Potential Beneficial Effects of Cytomegalovirus Infection after Transplantation. <i>Frontiers in Immunology</i> , 2018, 9, 389.	4.8	49
41	Î³Î±2T cell diversity and the receptor interface with tumor cells. <i>Journal of Clinical Investigation</i> , 2020, 130, 4637-4651.	8.2	49
42	Coexpression of the T-cell receptor constant Î± domain triggers tumor reactivity of single-chain TCR-transduced human T cells. <i>Blood</i> , 2010, 115, 5154-5163.	1.4	48
43	Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. <i>Blood Advances</i> , 2022, 6, 3378-3385.	5.2	45
44	Redirection of T Cells by Delivering a Transgenic Mouse-Derived MDM2 Tumor Antigen-Specific TCR and its Humanized Derviative Is Governed by the CD8 Coreceptor and Affects Natural Human TCR Expression. <i>Immunologic Research</i> , 2006, 34, 67-87.	2.9	43
45	Evaluating in vivo efficacy â€” toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells. , 2019, 7, 69.		42
46	Î³Î± T-cell Receptors Derived from Breast Cancerâ€”Infiltrating T Lymphocytes Mediate Antitumor Reactivity. <i>Cancer Immunology Research</i> , 2020, 8, 530-543.	3.4	42
47	Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Pharmacokinetics</i> , 2019, 58, 627-637.	3.5	41
48	Cancer Immunotherapy Using Î±Î±T Cells: Dealing with Diversity. <i>Frontiers in Immunology</i> , 2014, 5, 601.	4.8	40
49	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Bone Marrow Transplantation</i> , 2020, 55, 681-694.	2.4	39
50	Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party. <i>Haematologica</i> , 2014, 99, 1582-1590.	3.5	36
51	Refinement of the Definition of Permissible HLA-DPB1 Mismatches with Predicted Indirectly ReCognizable HLA-DPB1 Epitopes. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1705-1710.	2.0	31
52	Untouched GMP-Ready Purified Engineered Immune Cells to Treat Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3957-3968.	7.0	30
53	Processing and MHC class I presentation of human cytomegalovirus pp65-derived peptides persist despite gpUS2â€”11-mediated immune evasion. <i>Journal of General Virology</i> , 2007, 88, 1429-1439.	2.9	29
54	Control Of Organ Transplant-Associated Graft-versus-Host Disease By Activated Host Lymphocyte Infusions. <i>Transplantation</i> , 2004, 78, 1774-1779.	1.0	28

#	ARTICLE	IF	CITATIONS
55	An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 6478-6486.	7.0	28
56	Rapid reconstitution of CD4 T cells and NK cells protects against CMV-reactivation after allogeneic stem cell transplantation. <i>Journal of Translational Medicine</i> , 2016, 14, 230.	4.4	27
57	Results of a multicenter phase I/II trial of TCR $\hat{\pm}$ $\hat{I}^2$ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients. <i>Bone Marrow Transplantation</i> , 2022, 57, 423-430.	2.4	27
58	Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2021, 39, 397-418.	1.6	23
59	Indirectly Recognized HLA-C Mismatches and Their Potential Role in Transplant Outcome. <i>Frontiers in Immunology</i> , 2014, 5, 210.	4.8	21
60	Sufficient Immunosuppression with Thymoglobulin Is Essential for a Successful Haplo-Myeloid Bridge in Haploidentical-Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1839-1845.	2.0	21
61	$\hat{\pm}$ $\hat{I}^2$ T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies. <i>Blood Advances</i> , 2021, 5, 240-249.	5.2	21
62	Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds. , 2021, 9, e003850.		20
63	Cytomegalovirus Interleukin-10 Expression in Infected Cells Does Not Impair MHC Class I Restricted Peptide Presentation on Bystanding Antigen-Presenting Cells. <i>Viral Immunology</i> , 2006, 19, 92-101.	1.3	19
64	Filgrastim enhances T-cell clearance by antithymocyte globulin exposure after unrelated cord blood transplantation. <i>Blood Advances</i> , 2018, 2, 565-574.	5.2	19
65	Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure. <i>Oncolimmunology</i> , 2022, 11, 2033528.	4.6	19
66	The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study. <i>Haematologica</i> , 2011, 96, 1380-1384.	3.5	18
67	A semi-mechanistic model based on glutathione depletion to describe intra-individual reduction in busulfan clearance. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1499-1509.	2.4	18
68	Exploratory Study of Predicted Indirectly ReCognizable HLA Epitopes in Mismatched Hematopoietic Cell Transplantations. <i>Frontiers in Immunology</i> , 2019, 10, 880.	4.8	17
69	Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	17
70	Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia &gt;45 years undergoing allogeneic stem cell transplantation—a retrospective study by the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2020, 55, 1560-1569.	2.4	16
71	Cytomegalovirus Status and the Outcome of T Cell-Replete Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1883-1887.	2.0	15
72	Designing TCR for Cancer Immunotherapy. , 2005, 109, 229-256.		14

#	ARTICLE	IF	CITATIONS
73	Re-targeting T-cells against cancer by gene-transfer of tumor-reactive receptors. Expert Opinion on Biological Therapy, 2009, 9, 579-591.	3.1	14
74	NK Cells and Î³Î± T Cells for Relapse Protection after Allogeneic Hematopoietic Cell Transplantation (HCT). Current Stem Cell Reports, 2017, 3, 301-311.	1.6	13
75	Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses. Theranostics, 2017, 7, 1705-1718.	10.0	13
76	Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib. Bone Marrow Transplantation, 2018, 53, 1255-1262.	2.4	13
77	Opportunities and challenges associated with the evaluation of chimeric antigen receptor T cells in real-life. Current Opinion in Oncology, 2020, 32, 427-433.	2.4	13
78	Orchestrating an immune response against cancer with engineered immune cells expressing Î±Î±2TCRs, CARs, and innate immune receptors: an immunological and regulatory challenge. Cancer Immunology, Immunotherapy, 2015, 64, 893-902.	4.2	12
79	Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia. Journal of Hematology and Oncology, 2021, 14, 76.	17.0	12
80	Multifunctional Î±Î± T cells and their receptors for targeted anticancer immunotherapy. OncoImmunology, 2013, 2, e23974.	4.6	11
81	Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP. Bone Marrow Transplantation, 2018, 53, 1201-1205.	2.4	10
82	Fine-Tuning Antithymocyte Globulin Dosing and Harmonizing Clinical Trial Design. Journal of Clinical Oncology, 2018, 36, 1175-1176.	1.6	10
83	TEG001 Insert Integrity from Vector Producer Cells until Medicinal Product. Molecular Therapy, 2020, 28, 561-571.	8.2	10
84	Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. Bone Marrow Transplantation, 2021, 56, 2194-2202.	2.4	10
85	Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib. Blood, 2016, 128, 4561-4561.	1.4	10
86	Prevention of VÎ±VÎ±2 T Cell Activation by a VÎ±VÎ±2 TCR Nanobody. Journal of Immunology, 2017, 198, 308-317.	0.8	9
87	Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profile. Bone Marrow Transplantation, 2020, 55, 2188-2192.	2.4	9
88	TEG011 persistence averts extramedullary tumor growth without exerting off-target toxicity against healthy tissues in a humanized HLA-A*24:02 transgenic mice. Journal of Leukocyte Biology, 2020, 107, 1069-1079.	3.3	9
89	Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status. Bone Marrow Transplantation, 2020, 55, 1367-1378.	2.4	9
90	Cell-density independent increased lymphocyte production and loss rates post-autologous HSCT. ELife, 2021, 10, .	6.0	9

#	ARTICLE	IF	CITATIONS
91	Impact of donor-derived CD34+ infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation, 2022, 57, 261-270.	2.4	9
92	Single Nucleotide Polymorphisms of the High Affinity IgG Receptor FcγRI Reduce Immune Complex Binding and Downstream Effector Functions. Journal of Immunology, 2017, 199, 2432-2439.	0.8	8
93	Thrombocytopenia and the effect of platelet transfusions on the occurrence of intracranial hemorrhage in patients with acute leukemia – a nested case-control study. Annals of Hematology, 2021, 100, 261-271.	1.8	8
94	Nicord Single Unit Expanded Umbilical Cord Blood Transplantation: Final Results of a Multicenter Phase I/II Trial. Blood, 2017, 130, 847-847.	1.4	8
95	Defining the impact of SARS-COV-2 on delivery of CAR T-cell therapy in Europe: a retrospective survey from the CTIWP of the EBMT. Bone Marrow Transplantation, 2022, 57, 299-301.	2.4	8
96	Complete donor chimerism is a prerequisite for the effect of Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) on acute graft-versus-host disease. Chimerism, 2014, 5, 94-98.	0.7	7
97	Activation of silent mating type information regulation 2 homolog 1 by human chorionic gonadotropin exerts a therapeutic effect on hepatic injury and inflammation. Hepatology, 2017, 65, 2074-2089.	7.3	7
98	Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers, 2021, 13, 672.	3.7	7
99	The Role of γδ T Cells as a Line of Defense in Viral Infections after Allogeneic Stem Cell Transplantation: Opportunities and Challenges. Viruses, 2022, 14, 117.	3.3	7
100	Vaccine Responses in Adult Hematopoietic Stem Cell Transplant Recipients: A Comprehensive Review. Cancers, 2021, 13, 6140.	3.7	7
101	Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation. Bone Marrow Transplantation, 2018, 53, 1548-1552.	2.4	6
102	Efficient lentiviral transduction method to gene modify cord blood CD8+ T cells for cancer therapy applications. Molecular Therapy - Methods and Clinical Development, 2021, 21, 357-368.	4.1	6
103	Allogeneic Stem Cell Transplantation Platforms With Ex Vivo and In Vivo Immune Manipulations: Count and Adjust. HemaSphere, 2021, 5, e580.	2.7	6
104	Delayed Transfer of Immune Cells or the Art of Donor Lymphocyte Infusion. , 2019, , 443-448.		6
105	Double Umbilical Cord Blood Transplantation in High-Risk Hematological Patients: A Phase II Study Focusing on the Mechanism of Graft Predominance. HemaSphere, 2019, 3, e285.	2.7	5
106	Predictive factors for vaccine failure to guide vaccination in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplantation, 2021, 56, 2922-2928.	2.4	5
107	Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT. Bone Marrow Transplantation, 2020, 55, 729-739.	2.4	4
108	Characterization and modulation of anti-γδ TCR antibodies and their respective binding sites at the γδ TCR chain to enrich engineered T cells. Molecular Therapy - Methods and Clinical Development, 2021, 22, 388-400.	4.1	4



#	ARTICLE	IF	CITATIONS
109	Results of a Prospective, Multicenter, Phase I/II Clinical Study in Pediatric and Adult Patients Using TCR Alpha/Beta and CD19 Depleted Haploidentical Hematopoietic Stem Cell Grafts Following Reduced-Intensity Conditioning. <i>Blood</i> , 2018, 132, 604-604.	1.4	3
110	Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients. <i>Blood</i> , 2015, 126, 858-858.	1.4	3
111	The next step toward GMP-grade production of engineered immune cells. <i>OncImmunology</i> , 2016, 5, e1076608.	4.6	2
112	High Exposure to Fludarabine in Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation Predicts for Impaired CD4 Reconstitution and Lower Survival Chances. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S72-S73.	2.0	2
113	Second autologous haematopoietic stem cell transplantation in systemic sclerosisâ€”a case report. <i>Rheumatology</i> , 2019, 58, 1305-1307.	1.9	2
114	Editorial: Î³ T Cells in Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 602411.	4.8	2
115	Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2651-2655.	2.4	2
116	Autologous Blood Stem Cell Transplantation Results In Better Relapse-Free Survival Than Consolidation Chemotherapy: Results of a HOVON/SAKK Phase III Trial In 519 AML Patients In First Complete Remission. <i>Blood</i> , 2010, 116, 367-367.	1.4	2
117	Effective Treatment of Severe Chronic Graft Versus Host Disease with a Combination of B-Cell Depletion and Tyrosine Kinase Inhibition. <i>Blood</i> , 2016, 128, 4565-4565.	1.4	2
118	Adding Help to an HLA-A*24:02 Tumor-Reactive Î³ TCR Increases Tumor Control. <i>Frontiers in Immunology</i> , 2021, 12, 752699.	4.8	2
119	Clinical and Biological Concepts for Mastering Immune Reconstitution After HSCT: Toward Practical Guidelines and Greater Harmonization. , 2019, , 69-74.		2
120	Individualized Fludarabine Dosing for Predictable Immune Reconstitution and Increased Survival Chances after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S306-S307.	2.0	1
121	Tyrosine kinase inhibitor levels matter in treating chronic GVHD. <i>Bone Marrow Transplantation</i> , 2019, 54, 1141-1144.	2.4	1
122	International Forum on Transfusion Practices in Haematopoietic Stemâ€”Cell Transplantation: Summary. <i>Vox Sanguinis</i> , 2021, 116, 609-612.	1.5	1
123	TCR Gene Editing Results in Effective Immunotherapy of Leukemia without the Development of GvHD. <i>Blood</i> , 2011, 118, 667-667.	1.4	1
124	Immune Reconstitution and Clinical Outcome after Î±/Î² T-Cell Depleted Allogeneic Stem Cell Transplantation from Matched Related and Unrelated Donors. <i>Blood</i> , 2015, 126, 4313-4313.	1.4	1
125	The Disease Risk Index Is a Robust Tool for Allogeneic Hematopoietic Stem Cell Transplantation Risk Stratification: An Independent Validation Study on a Large Cohort of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 988-988.	1.4	1
126	Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Improves Outcome As Compared to Conventional Consolidation in Patients Aged 40â€”60 Years with AML in CR1 with Apparent Greater Benefit for Reduced Intensity Rather Than Myeloablative Conditioning. <i>Blood</i> , 2011, 118, 159-159.	1.4	1



#	ARTICLE	IF	CITATIONS
127	Î²2 T-Cell Expansion and Phenotypic Profile Are Reflected in the CDR3Î² Repertoire of Healthy Adults. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
128	Identifying Permissible HLA-Mismatches in Unrelated-Donor Hematopoietic Stem-Cell Transplantation Using Predicted Indirectly Recognizable HLA Epitopes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S107-S108.	2.0	0
129	Optimizing Anti-Thymocyte Globulin Exposure to Improve Survival Chances after Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S45-S46.	2.0	0
130	Nicord Single Unit Expanded Umbilical Cord Blood Transplantation (UCBT): Final Results of a Multicenter Phase I/ II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S57.	2.0	0
131	G-CSF Treatment Further Impairs T-Cell Reconstitution in Patients with Residual Anti-Thymocyte Globulin Exposure after Hematopoietic Cell Transplantation: Implications for G-CSF Use?. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S37.	2.0	0
132	International Forum on Transfusion Practices in Haematopoietic Stemâ€Cell Transplantation: Responses. <i>Vox Sanguinis</i> , 2021, 116, e25-e43.	1.5	0
133	Editing Human Lymphocyte Specificity for Safe and Effective Adoptive Immunotherapy of Leukemia.. <i>Blood</i> , 2010, 116, 3764-3764.	1.4	0
134	Treatment of Steroid Resistant Grade II to IV Acute Gvhd by Infusion of Mesenchymal Stroma Cells Expanded with Human Plasma and Platelet Lysate - a Phase I/II Study. <i>Blood</i> , 2011, 118, 3046-3046.	1.4	0
135	Treatment of Chronic Graft Versus Host Disease with a Combination of B-Cell Depletion and Tyrosine Kinase Inhibition. <i>Blood</i> , 2015, 126, 1939-1939.	1.4	0
136	Manufacturing of Mesenchymal Stromal Cells for the Treatment of Graft-Versus-Host Disease: A Survey within the European Society of Blood and Marrow Transplantation. <i>Blood</i> , 2016, 128, 3374-3374.	1.4	0
137	Transplantation Outcome By Disease Risk and Donor Type over Time: An Analysis of 100,000 Allogeneic Stem Cell Transplantation on Behalf of the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2017, 130, 668-668.	1.4	0
138	Abstract LB-104: Targeting solid malignancies with TEGs: Î±Î²T cells engineered to express a defined Î³Î±TCR in xenograft mice model. , 2018, , .		0
139	First Results of a Prospective I/II Clinical Trial in Adult Patients Using TCR Alpha/Beta Depleted Stem Cell Transplantation from Matched Related and Unrelated Donors. <i>Blood</i> , 2018, 132, 2164-2164.	1.4	0
140	The connected worlds of stem cell transplantation and HIV. <i>Lancet HIV</i> ,the, 2020, 7, e594-e595.	4.7	0
141	Association between cardiovascular risk factors and intracranial hemorrhage in patients with acute leukemia. <i>European Journal of Haematology</i> , 2022, 108, 310-318.	2.2	0